[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Heartseed Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100619636","phase-1-endocardial-delivery-for-myocardial-regeneration-using-allogeneic-ipsc-derived-cardiomyocyte-spheroids-for-hf-with-systolic-dysfunction-emerald-study-100619636",false,"NCT07347197","Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)","A Phase I\u002FII Study of Endocardial Delivery for Myocardial Regeneration Using Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids for Heart Failure Reduced Ejection Fraction","EMERALD","Inclusion Criteria:\n\n* Patients with resting left ventricular ejection fraction (LVEF) ≦40% based on institutional assessment on screening echocardiographic assessment\n* New York Heart Association (NYHA) cardiac function classification of grade II or III at screening\n* Other Criteria apply, please contact the investigator\n\nExclusion Criteria:\n\n* Patients with cardiac devices such as pacemakers, implantable cardioverter defibrillators (ICDs), or cardiac resuscitation-enabled implantable cardioverter defibrillators (CRT-Ds)\n* Patients with heart failure due to the primary disease hypertrophic cardiomyopathy (including the dilated phase), restrictive cardiomyopathy, amyloidosis, takotsubo cardiomyopathy, congenital heart disease, cardiac sarcoidosis, or constrictive pericarditis\n* Other Criteria apply, please contact the investigator","ALL","20 Years","80 Years",{"count":21,"type":22},14,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.",[29,30,31,32],"Heart Failure","Ischemic Heart Failure","Ischemic Heart Disease","Dilated Cardiomyopathy (DCM)",[29,34,31,32,35,36],"Ischemic heart failure","iPSC","cell therapy","NOT_YET_RECRUITING","2026-01-08",{"date":40,"type":41},"2026-01-16","ACTUAL",{"date":43,"type":22},"2026-01-01",{"date":45,"type":22},"2030-01-31",{"name":47,"class":48},"Heartseed Inc.","INDUSTRY",""]